The role of immune checkpoint PD-1/PD-L1 in small cell lung cancer
ZHANG Minghui
WANG Yan
LI Guoliang
Abstract：Small-cell lung cancer(SCLC)is characterized by its rapid growth and early development of widespread metastases.Although patients with SCLC are highly responsive to chemotherapy and radiation therapy,long-term prognosis remains poor,with relapse and disease metastasis occurring in almost all cases.Immune checkpoint blockade,especially blockade of programmed death-1(PD-1)receptor and its ligand PD-L1,achieved robust responses and improved survival for patients with SCLC in preclinical and clinical studies.The blockade of PD-1/PD-L1 pathway as a novel therapeutic approach may change the treatment paradigm of SCLC in the future.Data on clinical activity by programmed cell death-1 ligand expression in SCLC are not widely available.In addition,limited data indicate that PD-L1 expression may be an ideal biomarker for patient selection.Here,we summarize the brief history of PD-L1 as a biomarker and describe the critical role of PD-1/PD-L1 inhibitors in SCLC.
Keywords：Small-cell lung cancerprogrammed death-1(PD-1)programmed cell death ligand-1(PD-L1)Immunotherapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 277-280 )